Skip to main content
Top
Published in: Malaria Journal 1/2018

Open Access 01-12-2018 | Research

Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar

Authors: Jesmin Permala Lohy Das, Myat P. Kyaw, Myat H. Nyunt, Khin Chit, Kyin H. Aye, Moe M. Aye, Mats O. Karlsson, Martin Bergstrand, Joel Tarning

Published in: Malaria Journal | Issue 1/2018

Login to get access

Abstract

Background

Artemisinins are the most effective anti-malarial drugs for uncomplicated and severe Plasmodium falciparum malaria. However, widespread artemisinin resistance in the Greater Mekong Region of Southeast Asia is threatening the possibility to control and eliminate malaria. This work aimed to evaluate the pharmacokinetic and pharmacodynamic properties of artesunate and its active metabolite, dihydroartemisinin, in patients with sensitive and resistant falciparum infections in Southern Myanmar. In addition, a simple nomogram previously developed to identify artemisinin resistant malaria infections was evaluated.

Methods

Fifty-three (n = 53) patients were recruited and received daily oral artesunate monotherapy (4 mg/kg) for 7 days. Frequent artesunate and dihydroartemisinin plasma concentration measurements and parasite microscopy counts were obtained and evaluated using nonlinear mixed-effects modelling.

Results

The absorption of artesunate was best characterized by a transit-compartment (n = 3) model, followed by one-compartment disposition models for artesunate and dihydroartemisinin. The drug-dependent parasite killing effect of dihydroartemisinin was described using an Emax function, with a mixture model discriminating between artemisinin sensitive and resistant parasites. Overall, 56% of the studied population was predicted to have resistant malaria infections. Application of the proposed nomogram to identify artemisinin-resistant malaria infections demonstrated an overall sensitivity of 90% compared to 55% with the traditional day-3 positivity test.

Conclusion

The pharmacokinetic-pharmacodynamic properties of artesunate and dihydroartemisinin were well-characterized with a mixture model to differentiate between drug sensitive and resistant infections in these patients. More than half of all patients recruited in this study had artemisinin-resistant infections. The relatively high sensitivity of the proposed nomogram highlights its potential clinical usefulness.
Literature
1.
go back to reference WHO. World malaria report 2016. Geneva: World Health Organization; 2016. WHO. World malaria report 2016. Geneva: World Health Organization; 2016.
2.
go back to reference WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2015. WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2015.
3.
go back to reference WHO. World malaria report 2015. Geneva: World Health Organization; 2015. WHO. World malaria report 2015. Geneva: World Health Organization; 2015.
4.
go back to reference Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.CrossRefPubMedPubMedCentral Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.CrossRefPubMedPubMedCentral
5.
go back to reference Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS ONE. 2013;8:e57689.CrossRefPubMedPubMedCentral Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS ONE. 2013;8:e57689.CrossRefPubMedPubMedCentral
7.
go back to reference Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis. 2010;201:570–9.CrossRefPubMedPubMedCentral Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis. 2010;201:570–9.CrossRefPubMedPubMedCentral
8.
go back to reference Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–20.CrossRefPubMed Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–20.CrossRefPubMed
9.
go back to reference Thanh NV, Thuy-Nhien N, Tuyen NT, Tong NT, Nha-Ca NT, Dong LT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam. Malar J. 2017;16:27.CrossRefPubMedPubMedCentral Thanh NV, Thuy-Nhien N, Tuyen NT, Tong NT, Nha-Ca NT, Dong LT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam. Malar J. 2017;16:27.CrossRefPubMedPubMedCentral
10.
go back to reference Phuc BQ, Rasmussen C, Duong TT, Dong LT, Loi MA, Menard D, et al. Treatment failure of dihydroartemisinin/piperaquine for Plasmodium falciparum malaria, Vietnam. Emerg Infect Dis. 2017;23:715–7.CrossRefPubMedPubMedCentral Phuc BQ, Rasmussen C, Duong TT, Dong LT, Loi MA, Menard D, et al. Treatment failure of dihydroartemisinin/piperaquine for Plasmodium falciparum malaria, Vietnam. Emerg Infect Dis. 2017;23:715–7.CrossRefPubMedPubMedCentral
11.
go back to reference Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis. 2017;17:491–7.CrossRefPubMedPubMedCentral Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis. 2017;17:491–7.CrossRefPubMedPubMedCentral
12.
go back to reference WHO. Workshop to review and plan therapeutic efficacy studies to monitor P. falciparum and P. vivax resistance to anti-malarial drugs in the Greater Mekong Sub-region; May 3, 2012. WHO. Workshop to review and plan therapeutic efficacy studies to monitor P. falciparum and P. vivax resistance to anti-malarial drugs in the Greater Mekong Sub-region; May 3, 2012.
13.
go back to reference Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.CrossRefPubMedPubMedCentral Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.CrossRefPubMedPubMedCentral
14.
go back to reference Phyo AP, Ashley EA, Anderson TJC, Bozdech Z, Carrara VI, Sriprawat K, et al. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003–2013): the role of parasite genetic factors. Clin Infect Dis. 2016;63:784–91.CrossRefPubMedPubMedCentral Phyo AP, Ashley EA, Anderson TJC, Bozdech Z, Carrara VI, Sriprawat K, et al. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003–2013): the role of parasite genetic factors. Clin Infect Dis. 2016;63:784–91.CrossRefPubMedPubMedCentral
15.
go back to reference Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8:272–80.CrossRefPubMed Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8:272–80.CrossRefPubMed
16.
go back to reference Lourens C, Lindegardh N, Barnes KI, Guerin PJ, Sibley CH, White NJ, et al. Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the Worldwide Antimalarial Resistance Network (WWARN). Antimicrob Agents Chemother. 2014;58:3889–94.CrossRefPubMedPubMedCentral Lourens C, Lindegardh N, Barnes KI, Guerin PJ, Sibley CH, White NJ, et al. Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the Worldwide Antimalarial Resistance Network (WWARN). Antimicrob Agents Chemother. 2014;58:3889–94.CrossRefPubMedPubMedCentral
17.
go back to reference Lindegårdh N, Dondorp AM, Singhasivanon P, White NJ, Day NPJ. Validation and application of a liquid chromatographic–mass spectrometric method for determination of artesunate in pharmaceutical samples. J Pharm Biomed Anal. 2007;45:149–53.CrossRefPubMed Lindegårdh N, Dondorp AM, Singhasivanon P, White NJ, Day NPJ. Validation and application of a liquid chromatographic–mass spectrometric method for determination of artesunate in pharmaceutical samples. J Pharm Biomed Anal. 2007;45:149–53.CrossRefPubMed
18.
go back to reference U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) , Center for Veterinary Medicine (CVM). Guidance for Industry: Bioanalytical Method Validation. FDA, Maryland; 2001. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) , Center for Veterinary Medicine (CVM). Guidance for Industry: Bioanalytical Method Validation. FDA, Maryland; 2001.
19.
go back to reference NONMEM 7: Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User’s Guides. (1989–2009). Ellicott City: Icon Development Solutions; 2009. NONMEM 7: Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User’s Guides. (1989–2009). Ellicott City: Icon Development Solutions; 2009.
20.
go back to reference Hooker AC, Karlsson MO, Wilkins JJ, Jonsson EN. Xpose4: tools for nonlinear mixed-effect model building and diagnostics. R package version 4.5.3. 2014. Hooker AC, Karlsson MO, Wilkins JJ, Jonsson EN. Xpose4: tools for nonlinear mixed-effect model building and diagnostics. R package version 4.5.3. 2014.
21.
go back to reference Keizer RJKM, Hooker AC. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2:e50.CrossRefPubMedPubMedCentral Keizer RJKM, Hooker AC. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2:e50.CrossRefPubMedPubMedCentral
22.
go back to reference Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241–57.CrossRefPubMed Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241–57.CrossRefPubMed
23.
go back to reference R Core Team. R. A language and enviroment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013. R Core Team. R. A language and enviroment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013.
24.
go back to reference Wickham WCH. ggplot2: elegant graphics for data analysis. New York: Springer; 2009.CrossRef Wickham WCH. ggplot2: elegant graphics for data analysis. New York: Springer; 2009.CrossRef
27.
go back to reference McGready R, Phyo AP, Rijken MJ, Tarning J, Lindegardh N, Hanpithakpon W, et al. Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Br J Clin Pharmacol. 2012;73:467–77.CrossRefPubMed McGready R, Phyo AP, Rijken MJ, Tarning J, Lindegardh N, Hanpithakpon W, et al. Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Br J Clin Pharmacol. 2012;73:467–77.CrossRefPubMed
28.
go back to reference Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35:401–21.CrossRefPubMed Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35:401–21.CrossRefPubMed
31.
go back to reference Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51:224–32.PubMed Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51:224–32.PubMed
32.
go back to reference Tran HT, White NJ, Nguyen TT, Nhu HT, Phung TD, Tarning J, et al. Estimation of the in vivo minimum inhibitory concentration of cipargamin in uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2017;61:e01940-16.CrossRef Tran HT, White NJ, Nguyen TT, Nhu HT, Phung TD, Tarning J, et al. Estimation of the in vivo minimum inhibitory concentration of cipargamin in uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2017;61:e01940-16.CrossRef
33.
go back to reference White NJ. Antimalarial drug resistance. J. Clin Investig. 2004;113:1084–92.CrossRef White NJ. Antimalarial drug resistance. J. Clin Investig. 2004;113:1084–92.CrossRef
34.
go back to reference Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: part 3—Introduction to Pharmacodynamic Modeling Methods. CPT Pharmacometrics Syst Pharmacol. 2014;3:e88.CrossRefPubMedPubMedCentral Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: part 3—Introduction to Pharmacodynamic Modeling Methods. CPT Pharmacometrics Syst Pharmacol. 2014;3:e88.CrossRefPubMedPubMedCentral
35.
go back to reference Gisleskog P, Karlsson M, Beal S. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn. 2002;29:473–505.CrossRefPubMed Gisleskog P, Karlsson M, Beal S. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn. 2002;29:473–505.CrossRefPubMed
36.
go back to reference Lohy Das J, Dondorp AM, Nosten F, Phyo AP, Hanpithakpong W, Ringwald P, et al. Population pharmacokinetic and pharmacodynamic modeling of artemisinin resistance in Southeast Asia. AAPS J. 2017;19:1842–54.CrossRefPubMed Lohy Das J, Dondorp AM, Nosten F, Phyo AP, Hanpithakpong W, Ringwald P, et al. Population pharmacokinetic and pharmacodynamic modeling of artemisinin resistance in Southeast Asia. AAPS J. 2017;19:1842–54.CrossRefPubMed
37.
go back to reference Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.CrossRefPubMedPubMedCentral Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.CrossRefPubMedPubMedCentral
38.
go back to reference Tan B, Naik H, Jang IJ, Yu KS, Kirsch LE, Shin CS, et al. Population pharmacokinetics of artesunate and dihydroartemisinin following single-and multiple-dosing of oral artesunate in healthy subjects. Malar J. 2009;8:304.CrossRefPubMedPubMedCentral Tan B, Naik H, Jang IJ, Yu KS, Kirsch LE, Shin CS, et al. Population pharmacokinetics of artesunate and dihydroartemisinin following single-and multiple-dosing of oral artesunate in healthy subjects. Malar J. 2009;8:304.CrossRefPubMedPubMedCentral
39.
go back to reference Van Acker K, Mommaerts M, Vanermen S, Meskens J, Heyden YV, Plaizier-Vercammen J. Chemical stability of artemisinin derivatives. Malar J. 2012;11(Suppl 1):P99.CrossRefPubMedCentral Van Acker K, Mommaerts M, Vanermen S, Meskens J, Heyden YV, Plaizier-Vercammen J. Chemical stability of artemisinin derivatives. Malar J. 2012;11(Suppl 1):P99.CrossRefPubMedCentral
40.
go back to reference Talundzic E, Okoth SA, Congpuong K, Plucinski MM, Morton L, Goldman IF, et al. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog. 2015;11:e1004789.CrossRefPubMedPubMedCentral Talundzic E, Okoth SA, Congpuong K, Plucinski MM, Morton L, Goldman IF, et al. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog. 2015;11:e1004789.CrossRefPubMedPubMedCentral
41.
go back to reference WHO Malaria Policy Advisory Committee Meeting Group. Minutes of the technical expert group (TEG) on drug efficacy and response. Geneva: World Health Organization; 2016. WHO Malaria Policy Advisory Committee Meeting Group. Minutes of the technical expert group (TEG) on drug efficacy and response. Geneva: World Health Organization; 2016.
42.
go back to reference Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017;41:34–48.CrossRefPubMedPubMedCentral Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017;41:34–48.CrossRefPubMedPubMedCentral
43.
go back to reference van Schalkwyk DA, Sutherland CJ. Malaria resistance to non-artemisinin partner drugs: how to reACT. Lancet Infect Dis. 2015;15:621–3.CrossRefPubMed van Schalkwyk DA, Sutherland CJ. Malaria resistance to non-artemisinin partner drugs: how to reACT. Lancet Infect Dis. 2015;15:621–3.CrossRefPubMed
Metadata
Title
Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar
Authors
Jesmin Permala Lohy Das
Myat P. Kyaw
Myat H. Nyunt
Khin Chit
Kyin H. Aye
Moe M. Aye
Mats O. Karlsson
Martin Bergstrand
Joel Tarning
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2018
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-018-2278-5

Other articles of this Issue 1/2018

Malaria Journal 1/2018 Go to the issue